Stock Analysis of Nymox Pharmaceutical Corp (NYMX) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code NYMX
Close 0.200
Change -0.0500 / 20.00 %
Volume 881574
Vol Change 460474 / 109.35 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthStrong Bearish
Growth Index Poor Growth Stock
Value Index Poor Value Stock
Profitability Index Low Profitability Stock
Stability Index Poor Stability Stock


Fundamental View of Nymox Pharmaceutical Corp
PE (TTM)

-3.41

Very Poor
Price / Book

-42.22

Very Poor
Price / Sales

0

Very Poor
Piotroski F Score

2.0

Poor
Market Cap

18253.02 K

Enterprise Value

17023.02 K

ROA (TTM)

-264.18

Very Poor
ROE (TTM)

0

Poor
Net Margin (TTM)

0

Poor
Revenue

%

0
Net Profit

47.55 %

-6576.00 K
Debt to Equity

-0.359

Very Poor
Altman Z Score

-180.11

Very Poor
Quick Ratio

0.678

Not Good
Cash Ratio

0.666

Not Good


Highs/Lows of Nymox Pharmaceutical Corp
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week0.215 6.98 % 0.513 % 0.34980.170103-Jul-2330-Jun-23
Two Week0.3499 42.84 % 0.486 % 0.3570.170123-Jun-2330-Jun-23
One Month0.4077 50.94 % 4.80 % 0.4170.170116-Jun-2330-Jun-23
Three Month0.36 44.44 % 3.56 % 0.49250.170108-May-2330-Jun-23
Six Months0.41 51.22 % 15.54 % 0.530.170116-Feb-2330-Jun-23
One year0.4 50.00 % 26.26 % 0.740.170108-Dec-2230-Jun-23
Two year1.53 86.93 % 27.72 % 2.10.170107-Mar-2230-Jun-23
Five year3.65 94.52 % 91.77 % 0.740.170108-Dec-2230-Jun-23
Ten year5.23 96.18 % 174.36 % 8.190.170105-Sep-1330-Jun-23


Technical View of Nymox Pharmaceutical Corp
RSI

30.51

Neutral
MACD

-0.0485

Bearish
ADX

19.02

Neutral
Super Trend

0.320

Strong Bearish
Williams %R

-87.89

Mild Bullish
CCI

-153.19

Mild Bullish


EMA 5

0.236

Strong Bearish
EMA 15

0.291

Mild Bearish
EMA 50

0.358

Strong Bearish
EMA 100

0.382

Strong Bearish
SMA 100

0.386

Strong Bearish
SMA 200

0.385

Mild Bearish
SMA 5 / 20

0.223 / 0.328

Strong Bearish
SMA 15 / 50

0.307 / 0.387

Strong Bearish
SMA 50 / 200

0.387 / 0.385

Bullish




Charts of Nymox Pharmaceutical Corp


Returns of Nymox Pharmaceutical Corp with Peers
Period / StockNYMXSYBXLUMONERV
1 Week-6.98%-2.50%-8.20%4.44%
1 Mth-50.94%-12.85%-19.93%8.06%
3 Mth-44.44%-18.32%-26.23%-4.49%
6mth-51.22%-37.60%-21.33%-67.52%
1 Year-50.00%-80.19%-38.69%-57.29%
2 Year-86.93%-90.46%-70.66%-20.31%
5 Years-94.52%-98.60%-85.80%-93.88%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Nymox Pharmaceutical Corp with Peers
Ratio / StockNYMXSYBXLUMONERV
PE-3.41-25.07-0.490-0.0006
P/B-42.2241.180.5160
ROA-264.18-104.43-78.48-0.291
ROE0-164.28-105.230
Debt To Equity-0.3590.1120.01030
Revenue0
% 		708000
40.00 % 		1737.00 K
113951 % 		0
%
Net Income-6576.00 K
47.55 % 		-59444.00 K
10.13 % 		-32824.00 K
105572 % 		-27708.95 K
13.70 %


Technicals of Nymox Pharmaceutical Corp with Peers
Technical / StockNYMXSYBXLUMONERV-
ADX19.0229.6628.8420.10
CMF-0.193-0.2820.0160-0.0468
MFI61.512.4125.3349.22
RSI30.5130.6834.7252.29
MACD Abv SignalFalseFalseFalseTrue
Price Above 50 MAFalseFalseFalseTrue-
Price Above 200 MAFalseFalseFalseFalse-


About : Nymox Pharmaceutical Corp

Address : Bay & Deveaux Streets, Nassau, Bahamas
Tel : 800 936 9669
URL : https://nymox.com
Code : NYMX, ISIN : BSP733981026, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 01_Dec_1997

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.


Note : All Data Generated at the End of Trading Hours (EOD Data)